...
首页> 外文期刊>Clinical chemistry and laboratory medicine: CCLM >miRNAs, single nucleotide polymorphisms (SNPs) and age-related macular degeneration (AMD)
【24h】

miRNAs, single nucleotide polymorphisms (SNPs) and age-related macular degeneration (AMD)

机译:miRNA,单核苷酸多态性(SNP)和年龄相关性黄斑变性(AMD)

获取原文
获取原文并翻译 | 示例

摘要

Advanced age-related macular degeneration (AAMD) is a complex sight-threating disease of public health significance. Micro RNAs (miRNAs) have been proposed as biomarkers for AAMD. The presence of certain single nucleotide polymorphisms (SNPs) may influence the explanatory value of these biomarkers. Here we present findings from an integrated approach used to determine whether AAMD-associated SNPs have the capacity to influence miRNA-mRNA pairing and, if so, to what extent such pairing may be manifested in a discrete AAMD transcriptome. Using a panel of 8854 SNPs associated with AAMD at p-values <= 5.0E-7 from a cohort of > 30,000 elderly people, we identified SNPs in miRNA target-encoding constituents of: (1) regulator of complement activation (RCA) genes (rs390679, CFHR1, p <= 2.14E-214 | rs12140421, CFHR3, p <= 4.63E-29); (2) genes of major histocompatibility complex (MHC) loci (rs4151672, CFB, p <= 8.91E-41 | rs115404146, HLA-C, p <= 6.32E-12 | rs1055821, HLA-B, p <= 1.93E-9 | rs1063355, HLA-DQB1, p <= 6.82E-14); and (3) genes of the 10q26 AAMD locus (rs1045216, PLEKHA1, p <= 4.17E-142 | rs2672603, ARMS2, p <= 7.14E-46). We used these findings with existing data on AAMD-related retinal miRNA and transcript profiles for the purpose of making inferences on SNP-mRNA-miRNA-AAMD relationships. Four of 12 miRNAs significantly elevated in AAMD retina (hsa-miR-155-5p, hsa-let-7a-5p, hsa-let-7b-5p hsa-let7-d-5p) also showed strong pairing capacity (TarBase 7.1 context++ score < -0.2, miRanda 3.3 pairing score > 150) with miRNA target transcripts encoded by AAMD-associated SNPs resident in HLA-DQB1 (rs1063355, hsamiR- 155-5p) and TGFBR1 (rs868, hsa-let-7). Three of the 12 miRNAs overexpressed in AAMD retina are inducible by NFkB and have high affinity targets in the complement factor H (CFH) mRNA 3' UTR. We used ENSEMBL to identify polymorphic regions in the CFH mRNA 3' UTR with the capacity to disrupt miRNA-mRNA pairing. Two variants (rs766666504 and rs459598) existed in DNA sequence encoding the seed region of hsa-miR-146a-5p in the CFH mRNA 3' UTR -as this miRNA is also elevated in both vitreous and serum of people with AAMD, it shows great value as a biomarker. Our findings suggest that knowledge on the nature of DNA sequence variation may increase the explanatory power of miRNA biomarkers in genetically diverse populations, while yielding information with which to develop: (1) mechanistic tests on processes implicated in AMD pathogenesis; and, (2) site-specific small molecules (synthetic mimetics or anti-miRNAs) with preventive or therapeutic efficacy for AAMD.
机译:高龄相关的黄斑变性(AAMD)是一种复杂的公共卫生意义威胁性威胁性。已经提出了Micro RNA(miRNA)作为AAMD的生物标志物。某些单一核苷酸多态性(SNP)的存在可能影响这些生物标志物的解释性值。在这里,我们从用于确定AAMD相关的SNP是否具有影响miRNA-mRNA配对的能力的综合方法,如果是,则在多大程度上表现出这种配对的程度在离散的AAMD转录组中。使用与AAMD相关的8854个SNP,从P值<= 5.0E-7,来自队列的6,000名老年人,我们鉴定了miRNA靶编码成分中的SNP:(1)补体激活(RCA)基因的调节剂(RS390679,CFHR1,P <= 2.14E-214 | RS12140421,CFHR3,P <= 4.63E-29); (2)主要组织相容性复合物(MHC)基因座的基因(RS4151672,CFB,P <= 8.91E-41 | RS115404146,HLA-C,P <= 6.32E-12 | RS1055821,HLA-B,P <= 1.93e -9 | RS1063355,HLA-DQB1,P <= 6.82E-14); (3)10Q26 AAMD基因座的基因(RS1045216,Plekha1,P <= 4.17E-142 | RS2672603,Arms2,P <= 7.14e-46)。我们使用这些发现与AAMD相关的视网膜miRNA和转录性分布的现有数据,以便在SNP-mRNA-miRNA-AAMD关系上进行推断。在AAMD视网膜中,12名miRNA中的四种(HSA-MIR-155-5P,HSA-Let-7A-5P,HSA-Let-7B-5P HSA-Let7-D-5P)也显示出强烈的配对能力(Tarbase 7.1上下文++分数<-0.2,Miranda 3.3配对分数> 150),MiRNA目标转录物由HLA-DQ1(RS106355,HSAMIR-155-5P)和TGFBR1(RS868,HSA-Let-7)编码的AAMD相关的SNP编码。在AAMD视网膜中过表达的12个miRNA中的三个是NFκB诱导的,并且在补体因子H(CFH)mRNA 3'UTR中具有高亲和力靶标。我们使用Ensembl以识别CFH mRNA 3'UTR中的多态区域,其容量破坏miRNA-mRNA配对。在编码CFH mRNA 3'utr-146a-5p的种子区域的DNA序列中存在两种变体(RS766666504和RS459598),这种miRNA也升高在AAMD的玻璃体和血清中,它表现出很好价值作为生物标志物。我们的研究结果表明,关于DNA序列变异性质的知识可能会增加遗传多样化群体中MiRNA生物标志物的解释性,同时产生的信息:(1)在AMD发病机制中涉及的方法的机械测试; (2)特定的特异性小分子(合成模拟物或抗miRNA),具有预防或治疗疗效的AAMD。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号